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A B S T R A C T
Purpose of the study: To evaluate the mid-term safety and effectiveness of a novel stent graft for treatment of
abdominal aortic aneurysm (AAA).
Methods: Thirty-three patients with AAA (20 males and 13 females; mean age: 71.3 y) were treated with the
Ovation™Abdominal Stent Graft System (TriVascular, Inc., Santa Rosa, CA, USA). Indications for endovascular
aneurysm repair: AAA 5.5 cm, neck 7mm, angulation 60° and with an inner wall diameter of no less
than 16mm and no greater than 30mm; the presence of neck calciﬁcation and thrombosis is not much of a
problem in this device because aortic seal is achieved with 2 polymer-ﬁlled sealing rings and the ﬁxation by
means of a suprarenal stent with 8 pairs of anchors. Patients were followed through discharge and returned
for follow-up visits. The follow-up protocol included a CT-A exam at 1 and 12 months after the intervention;
the mid-term follow up was performed at 3 and 6 months with contrast-enhanced ultrasound (CEUS). Mean
follow-up duration was 18.6 months (range: 3–25 months).
Main ﬁndings: Technical success was 100%. Mean implantation procedure timewas 31.1minutes, andmedian
hospital stay was 4.6 days. None of the patients required conversion to open surgery, and no aneurysm
enlargement, rupture, fracture, or migration were observed. No type I, III or IV endoleaks were observed.
Hospitalization death rate was 0%. Death rate at 30 days was 0%. No major complications were observed.
Conclusions: The ﬁrst results from this 3-center study with the Ovation stent graft are promising with high
technical success and excellent safety and effectiveness.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Endovascular aneurysm repair (EVAR) is a widely embraced mini-
mally invasive alternative to open abdominal aortic aneurysm (AAA)
repair. EVAR is associatedwith less blood loss, shortenedhospital stay,
earlymobility, and fewer earlier adverse events. 1 It is current practice
in many centers to reserve standard open infrarenal AAA repair for
patients with unsuitable anatomy for EVAR and for younger patients
with few comorbidities and good life expectancy. Typical anatomical
criteria for EVAR include, aortic neck length of at least 10–15mm,
neck diameter not exceeding the device recommendations, neck
angulation less than 60° and adequate iliac artery diameter for
delivery of the device. 2 EVAR of AAAs not fulﬁlling one ormore of the
above anatomical criteria for the neck is associated with an increased
incidence of type I endoleak, migration of the endograft and aortic
neck dilatation. Furthermore, anatomically smaller iliac arteries (such
as in short females) where iliac diameter may be less than 1 cm or in
patients with concomitant iliac occlusive disease causing iliac artery
stenosis with a residual lumen between 5–8mm are usually excluded
from EVAR with conventional devices.
The Ovation™ Abdominal Stent Graft System (TriVascular Inc,
Santa Rosa, CA, USA) is a novel endoprosthesis that was designed to
overcome the limitations of current endografts by accommodating a
broad range of aortic morphology and by utilizing an enhanced seal
mechanism that may potentially reduce the risk of endoleak and sac
enlargement.
The aim of this study was to demonstrate the technical success,
mid-term safety and effectiveness of the Ovation device for treatment
of a series presented in a contemporary, real life (realistic) setting.
1743-9191$ – see front matter © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
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D2 D3 D6 D7 D8 D9 N1 N2
1 17.6 24.9 11 12.3 9.3 12.4 10 42
2 17.8 24.1 9.7 10.9 12.9 12.3 12 5
3 22.5 23.5 16.1 16.0 15.3 15.4 9 0
4 23.0 24.4 15.5 16.2 15.2 16.0 7 21
5 24.6 26.6 12.8 13.2 14.2 15.2 7.5 0
6 24.4 26.5 17.0 18.9 12.2 12.6 8 51
7 20.5 25.0 15.0 17.5 16.0 12.8 12 0
8 22.0 23.5 10.0 15.0 14.0 13.2 7.5 41
9 22.0 22.7 40.2 10.8 16.3 14.6 8 60
10 21.6 23.7 22.4 14.5 12.6 13.6 12 0
11 24.1 25.9 8.8 7.7 15.7 10.2 12 24
12 19.45 20.8 17.0 12.1 14.75 10.4 10 10
13 24 24 15 14 14 13 9.5 35
14 24 24.5 16.5 14 17 12.5 8 0
15 25.5 27.5 21 16.5 20 15 7 0
16 28.2 29 17 14.5 15.5 11.5 7.5 20
17 29 30 14 10 13 8.5 12 15
18 30 32 12 12.5 10 9 13 40
19 19 20 18 17.5 17 12 8 0
20 25 27 16 13.5 14 12.5 7.5 0
21 29 29 17 15 16 13.5 12.5 20
22 23.5 25 19 18.5 17 15 10 40
23 26.5 27 14 12 15 14.5 9.5 0
24 28 29 23 14 20 16.5 8 20
25 27 30 21 15.5 19 17 7.5 42
26 30 34 13 12 13.5 13 15 5
27 19 24 23 12.5 24 14 10 58
28 19.5 23 21 13 18 15 7.5 21
29 23 25.5 16 14 15.5 12 9 0
30 22.5 26.5 12 12 16 14 8.5 51
31 26 30 17 15 21 16 7 0
32 24 27 18.5 16 19 17 7 41
33 22.5 24 14 12 14 13.5 7 60
a Abbreviations:
D2 (mm): Aortic diameter at lowest renal artery (or intended landing zone)
D3 (mm): Aortic diameter + 13mm (distal to D2 measurement)
D6 (mm): Right mid (at mid common iliac artery)
D7 (mm): Right distal (~0.5–1 cm proximal to hypogastric origin)
D8 (mm): Left mid (at mid common iliac artery)
D9 (mm): Left distal (~0.5–1 cm proximal to hypogastric origin)
N1 (mm): Proximal neck length (from lower renal artery to beginning of dilatation)
N2 (°): Proximal neck angulation (between proximal neck and aortic dilatation)
2. Patients, methods and materials
2.1. Patients
All participants gave informed consent according to the practice in
3 institutes. Patients presented with an AAA requiring intervention
and with aorto-iliac characteristics suitable for treatment with the
Ovation device. Patient baseline characteristics are presented in
Table 1. This retrospective 3-center study involved 33 patients who
were treated with the TriVascular Ovation device between December
2010 andMarch 2013. Patients were followed through hospitalization
and returned for regular follow-up visits, with contrast-enhanced
CT scans performed at 1 and 12 months after the intervention. Mid-
term follow up was performed at 3 and 6 months with contrast-
enhanced ultrasound (CEUS) and if an endoleack was detected then
a contrast CT scan was also performed.
2.2. Baseline imaging and treatment procedure
All patients underwent preoperative evaluation of their aneurysm
with conventional contrast-enhanced CT imaging with thin (1mm)
slice thickness and with intravenous administration of iodinated
contrast media.
The arterial phase was acquired after the administration of 120ml
of 350mg I/ml iodinated contrast media (Iomeron 350, Bracco, Milan,
Italy; Visipaque 320, GE Healthcare, USA) at an injection rate of
4ml/s, followed by 40ml of saline solution at the same injection rate.
Optimal arterial enhancement was achieved using the bolus tracking
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technique, positioning a region of interest (ROI) on the abdominal
aorta (at the supra-renal level) with a threshold 100HU higher than
the basal density. At least a venous phase was performed 90 seconds
after contrast medium administration.
Patients were eligible for the procedure if they were considered
to have a low to moderate risk for elective open repair of a
non-ruptured AAA or aortoiliac aneurysm according to Society
for Vascular Surgery (SVS)/International Society for Cardiovascular
Surgery (ISCVS) scores of 0, 1, or 2. 3,4
The inclusion criteria were: age >18 years old, patients with
the ability and willingness to comply with all follow-up exams as
indicated in the clinical investigation plan, proximal neck length
7mm but <15mm, and external iliac artery diameter even less than
7mm (but 4.9mm) with severe bilateral iliac artery disease.
The exclusion criteria were subjects with high probability of non-
adherence to physician’s follow-up requirements, or with current
participation in a concurrent randomized control trial (RCT) or
investigational device/drug study which could confound study
results; life expectancy less than 1 year; pregnancy; patients with
poor renal function as indicated by a serum creatinine >2.5mg/dl.
Moreover, patients with a condition that could infect the graft and
patients with known sensitivities or allergies to the device materials
(including polytetraﬂuoroethylene [PTFE], polyethylene glycol [PEG]-
based polymers, ﬂuorinated ethylene propylene [FEP] or nitinol) were
excluded.
2.3. Device description
The Ovation™ stent graft has a unique deployment system of 2
polymer-ﬁlled proximal sealing rings that accommodate short prox-
imal aortic neck length of 7mm, and a hydrophilic coated 14F OD
delivery system that accommodates access vessels 4.7mm (Fig. 1).
The Ovation device gained CE mark approval in September 2010.
The TriVascular Ovation Abdominal Stent Graft System is a low-
proﬁle endovascular device delivered via catheter to treat AAAs. The
stent graft is designed to reline the diseased vasculature, providing an
alternate endovascular blood conduit for isolating the aneurysm from
the high pressure ﬂow of blood, thereby reducing or eliminating the
risk of rupture. The stent graft is a modular three-piece conﬁguration
comprised of an aortic body section and two iliac limbs.
The aortic section consists of a proximal stent for supra-renal
ﬁxation and a PTFE graft with a network of channels. The stent is
Fig. 1. Stent graft with 2 polymer-ﬁlled proximal sealing rings that accommodate short
proximal aortic neck.
designed with small anchors to enable ﬁxation to the aortic wall. For
delivery, the stent is in a compressed state within the catheter. When
released from the compressed state, the stent expands to engage the
vesselwall. The nitinol stents are radiopaque and the implant contains
radiopaque marker coils adjacent to the graft edges. These marker
coils serve as positioning aids during placement of the device and
allow the stent to be located so that it will not obstruct the renal
arteries. To seal the proximal end of the graft and to provide support
into which the iliac limbs are deployed, the graft body contains a
network of inﬂatable sealing channels and ring-shaped ribs that are
ﬁlled with a liquid polymer which cures during the deployment
procedure. The graft has an inﬂation ﬁll port that connects the
inﬂation network of the graft to the ﬁll tube on the delivery catheter.
The ﬁll polymer consists of a PEG-based ﬁll polymer, contrast agent
(Visipaque 320, GE Healthcare, USA), and a buffer. Themixing process
initiates the cross-linking of the components to form the solid ﬁll
polymer. The ﬁll polymer viscosity remains low for approximately
6 minutes after mixing. As the polymer cures, the material thickens
and changes from a liquid to a soft gel to a solid. The fully cured ﬁll
polymer is ﬁrm but has the elasticity of a pencil eraser.
The iliac limbs are comprised of nitinol stents encapsulated in PTFE.
The limbs are deployed into the limb section of the aortic body.
Radiopaque markers allow the physician to visualize the appropriate
iliac–aortic body overlap during a catheter-based deployment of the
iliac limb. Stent radial force provides both ﬁxation and sealing of the
overlap between the aortic body and each iliac limb. Radial force of the
stent also provides ﬁxation and sealing between the iliac limb and the
distal landing zone of the iliac artery.
To facilitate device introduction into the access vessel, both the
aortic body and the iliac limbs are preloaded into low-proﬁle delivery
catheters (14–15 F OD and 13–15 F OD, respectively). The aortic body
is deployed via the Aortic Body Delivery Catheter. The aortic delivery
catheter has a lumen that allows for the use of a guide wire to help
deliver the stent graft to the deployment site.
During stent graft deployment, the device is positioned and the
sheath is retracted. After positioning the stent graft in the desired
location, the proximal stent is deployed using release knobs on the
handle. The ﬁll material is then delivered through the ﬁll injection
channel using an auto injector (supplied). The time necessary to
create a perfect proximal seal is 20 minutes.
The contralateral and ipsilateral iliac limbs are deployed via the
Iliac LimbDelivery Catheter. The contralateral iliac limb is deployed in
the aortic body by a simple pull-back manoeuvre in the appropriate
location. After the ﬁll material cures within the inﬂated ribs and
sealing cuffs, the Aortic BodyDelivery Catheter is disengaged from the
inﬂation ﬁll port of the graft andwithdrawn from the vasculature. The
ipsilateral limb is thendeployedusing themethoddescribed above for
the contralateral limb.
Completion angiogram is always performed in order to evaluate
good graft functioning and the absence of an endoleak (Fig. 2).
2.4. Follow up
Patients were followed through hospital discharge and returned for
follow-up visits at 1, 6, and 12 months. Actually, we have a period
follow up ranging from 3 to 25 months (media 18.6 months). At each
follow-up visit, patients underwent a physical examination, blood
chemistry, evaluation of concomitant medications, and collection of
adverse events. Contrast-enhanced CT scans were performed at 1 and
12months after the intervention. Mid-term follow up was performed
at 3 and 6 months with contrast-enhanced ultrasound (CEUS) and
if an endoleak was detected then a contrast CT scan was also
performed.
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Fig. 2. (a) Aortogram; (b) kissing balloon of the iliac branches; (c) ﬁnal angiogram reveals absence of endoleak and exclusion of the AAA.
Fig. 3. (a,b) CT volume rendering reconstruction demonstrating (a) neck angulation and (b) deep posterior dive. (c) CT MIP reconstruction revealed correct deployment of the
prosthesis and exclusion of the AAA.
2.5. Outcomes: feasibility in selected patients; immediate technical
success, effectiveness and safety
Feasibility was deﬁned as the possibility to perform EVAR in patients
with difﬁcult iliac access (diameter <7mm), with short (but 7mm)
and/or angulated (60°) proximal neck (Fig. 3).
Technical success was deﬁned as successful deployment of the
endograft, in particular absence of type I endoleak at the angiogram
performed at the end of the procedure.
Effectiveness was deﬁned as the absence of type I endoleak,
migration and aneurysm enlargement at CT scan performed during
follow up.
Themain safety outcomesmeasuredweremortality and serious ad-
verse events (aneurysm enlargement rupture, conversion to surgery,
and secondary interventions), in accordance with the classiﬁcation
system of the Society of Interventional Radiology. 5
3. Results
3.1. Procedure and convalescence
Immediate technical success was obtained in 100% of the patients.
EVAR was feasible in all selected patients.
Average age of the patients was 71.3 years.
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The main implantation procedural time was 31.1 minutes (range
25–40 minutes), the mean procedural blood loss was 146.2ml (110–
200ml) and the mean hospitalization stay was 4.6 days (range
3–6 days).
3.2. Safety
No major or minor complications, serious adverse events or deaths
were registered during or after the procedure, 30 days after the graft
deployment and during the follow-up period.
3.3. Effectiveness
At CT scan performed during follow up no type I endoleak,
migration of the endograft, aneurysm enlargement and/or rupture
were observed.
No patients required a secondary intervention or a conversion to
open surgery.
4. Discussion
An unfavorable neck anatomy, based on its diameter, length, angula-
tion, morphology, and presence of calciﬁcation and mural thrombus,
is the most frequent cause of exclusion from EVAR. 6 Length <15mm,
angulation between 50° and 60°, diameter 26mm, the presence of
calciﬁcation, circumferential thrombus, bulge or reverse taper neck
are considered anatomic hostile neck characteristics. Patients were
considered to have hostile anatomy if they met one or more of these
criteria. 7
More than 30% of patients with AAA are not suitable for EVAR
because of hostile neck anatomy. These patients have a high risk
of distal migration and proximal type I endoleak. 8 Following EVAR,
the morphology of the aorta may change with regard to aneurysm
sac size, neck length, and neck dilatation. 9,10 Aortic neck dilatation
appears to be a marker of, and possibly a risk factor for, migration.
Moreover, some authors suggested that a diseased aortamay continue
to degenerate over time 11; alternatively, dilatation could be related
to changes in the pulsatile load exerted on the proximal anastomosis
after repair with a stiff, bifurcated prosthetic graft. 8 The Society for
Vascular Surgery (SVS) criteria deﬁned endograft migration to be
movement greater than 10mm relative to anatomic landmarks or any
migration resulting in a clinically adverse event. 12
The success of EVAR also depends on the adequacy of iliac femoral
access and the morphology of the iliac arteries, which determine
the deliverability of the stent graft components and the ability to
maintain an optimal seal zone. Iliac axis characteristics that could
preclude implantation of a stent graft include diameter, length,
tortuosity, and presence of calciﬁcation/thrombus. Moreover, the
presence of combined abdominal and iliac aneurysmal disease is a
frequently encountered problem and must not be underestimated.
In 20% of all patients with abdominal aortic aneurysm, an additional
iliac aneurysms is reported. 6 Minimal external iliac diameter should
be at least 7mm to allow sheath/device passage and to avoid arterial
dissection, avulsion, and rupture.
Much attention and research has been devoted in the development
of most endovascular aortic repair devices in order to accommodate
for patients with hostile necks as well as concomitant iliac stenosis
which may exclude larger proﬁle devices.
Turnbull et al. 7 published a prospective, non-randomized study
of patients with AAA who underwent EVAR using the Talent eLPS
stent graft (eLPS; Medtronic Vascular, Santa Rosa, CA, USA) in which
they reported good results in terms of safety and effectiveness.
Their patients presented a proximal AAA neck 5mm in length
and between 14 and 32mm in diameter, with 60° angulation as
demonstrated by radiologic imaging; a distance between the renal
arteries and the aortic bifurcation of 9 cm; a distal iliac neck length of
15mm; and distal iliac neck diameters between 8 and 18mm. 13
Cook recently received approval for their low-proﬁle EVAR device
(Zenith AAA LP), which has a 16 F (internal, 18 F external) delivery
system and eliminates the need for a top cap to help a precise deliv-
ery. 14 At present, no literature data are available about effectiveness
and safety of this new device.
Qu et al. summarized their unique experience with EVAR for
short/angulated neck AAAs with the Powerlink unibody bifurcated
stent graft. 15 The unique strategy for treating short (15mm) or
very short (10mm) [5%]/angulated (60°) [7%] neck AAAs is to
build up the endoluminal exclusion system from the native aortic
bifurcation to the renal artery level with suprarenal ﬁxation. The
Powerlink unibody bifurcated stent graft was implanted anatomically
ﬁxed on the aortic bifurcation and a long suprarenal cuff was built up
to the renal arteries. A Palmaz stent can be used for proximal ﬁxation
and sealing enhancement in the most challenging necks. Qu et al.
demonstrated that using the Powerlink fully supported unibody
bifurcated stent graft with a long suprarenal cuff, and a Palmaz stent
when needed, proved safe and effective in treating AAAs with short
and angulated necks. 15
Laborde et al. reported the ﬁrst in-human application of Tripelay
(Tripelay-DS – Tripelay, Paris, France), a new lower-proﬁle percu-
taneous self-expanding modular endoluminal vascular prosthesis,
intended to treat infrarenal AAA. 16 The delivery system is modular
and currently is 14 F. These new design characteristics allow for a
lower proﬁle and a ﬂexible delivery system. Of course, this procedure
still needs further clinical evaluation and longer follow up to conﬁrm
long-term efﬁcacy and safety of this device, that overcomes only the
limit of endovascular approach in difﬁcult iliac access.
Recanalization of an occluded iliac system re-establishes aortoiliac
inﬂow to both lower extremities, before the implantation of a bi-
furcated endovascular device, obviating the need for extra-anatomic
bypass, and may preserve hypogastric perfusion in some patients. 17
When feasible, iliac recanalization could be an option.
As is clear from the literature data reported here, despite the
commercial availability of several endovascular stent grafts for
treatment of AAA, none are able to treat patients with access vessel
diameters of7mm. The Ovation device overcomes this limitation by
allowing treatment of patientswith access vessel diameters4.9mm.
Furthermore, the ﬂexible 14 F OD delivery system may yield clinical
beneﬁts for patients with calciﬁed, thrombosed, or tortuous access
vessels. Similarly, currently available stent grafts can only treat
proximal landing zones of 10mm length while the novel sealing
mechanism of the Ovation device allows treatment in proximal
landing zones as short as 7mm. Therefore, this device may allow
patients to have greater access to EVAR.
In our series a technical success of 100% is reported. The absence of
type I endoleak during follow up is another encouraging result.
5. Conclusions
This study has several limitations. This is a retrospective nonran-
domized study; patients with aortoiliac occlusions that were not
anatomically suitable for this procedure were potentially seen at
the three institutions, so there was a potential for selection bias.
We did not evaluate patients with aneurysms and iliac artery
occlusions that were treated by more traditional means such as open
aortic surgery or aortouni-iliac stent graft. Moreover, we did not
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include patients with severe stenosis, pre-treated with angioplasty,
sequential dilation or stenting of the arteries, or both. This was also
a relatively small study, with only 33 patients garnered from three
tertiary referral centers.
From our experience the use of Ovation seems to be feasible and
may overcome the limits of all the other endovascular grafts now
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